Q118 results have factored in the news of lower sales and DE - Growth in USA in its stock price .
A 12 % lower growth in revenues EBITDA Margins Post R&D at 16 % vs 21%
Of the 3 vertices of the company Indian formulations, International formulations and Api Business there seems to be only 2 % growth in API business. Other 2 verticals have dragged down growth .
The company has said it has filed for 4 DMF, and as per the USFDA ORANGE BOOK the 4 DMF for this Q118 are
- Macitentan - 93 mm $ in sales
- Riociguat - 50 mm $ in sales
- Afatinib dimaleate - 36 mm $ in sales
- Ivacaftor - 24 mm $ in sales
So I can see not all the drugs at having a big market sales when compared to other products like Aripiprazole gAbilify, and there could be meaningful competition too in these drugs. I would watch the launches and DMF being filed by the company in future Quarters and the company has said that it would be launched 100 Anda commencing 2018 so which would be a great revenue drive I believe.
Disc : Invested in ALEMBIC pharma , opinions are my own and can be biased.